MolecularResponse provides a range of mouse models for xeno graft services. A key differentiator; however, is the availability of more than 140,000 primary tumor cells for implantation selectable from the Molecular Response Tumor Bank.
Primary tumor cells are proliferated to create a cell concentration sufficient to take in the xenograft model. We are now evaluating the use of tumor cells that have not been proliferated.
For more information on the Tumor Bank, including represented indications and drug response information, click here.
Our scientists are available to aid in study design, as needed, for consideration of elements such as:
- Primary tumors of interest
- Mouse model (e.g., NOD scid, BALB scid, or nu/nu)
- Number of animals
- Dose selection
- Treatment frequency
The most routine measurement of drug effect is tumor volume; however, it is equally important for us to monitor molecular characteristics of the tumor pre- and post-treatment.
Pre-treatment molecular analyses allow us to validate predictive markers evaluated in earlier in vitro and in vivo studies.